Semarang, Tuesday 28 June 2022 -- PT Kalbe Farma, Tbk (Kalbe) and Bank BNI synergize in business development and the Company's strategic plan. Kalbe receives a loan facility from Bank BNI worth Rp 1 trillion which can later be used for business expansion, including additional capital expenditures or other corporate actions.
The provision of this loan facility was marked by the signing of a credit agreement between the Head of Corporate Banking Division 1 I Made Sukajaya and Kalbe Farma President Director Vidjongtius, witnessed directly by BNI Corporate Banking Director Silvano Rumantir and Kalbe Farma Finance Director Bernadus Karmin Winata at BNI Tower, Wednesday (29/6/2022).
"We are grateful for BNI's support for the provision of this loan facility, which can later be used for business expansion, including additional capital expenditures or other corporate actions.
This loan facility will directly support the Company's business development from time to time in order to meet the health needs of the Indonesian people," said President Director of PT Kalbe Farma Tbk., Vidjongtius.
Pharmaceutical industry is one of the industries that is quite resilient in dealing with the negative impacts of the Covid-19 pandemic. This industry is also able to continue to grow its business in supporting the acceleration of national economic recovery as well as providing medicines, health products and nutrition to meet the needs of the community.
In 2021, Kalbe Farma's sales value reached Rp. 26 trillion. In the first quarter of 2022, the Company's sales reached Rp 7 trillion or grew 16% compared to the first quarter of 2021 where sales reached Rp 6 trillion.
BNI Corporate Banking Director Silvano Rumantir said that this is a very good momentum for BNI to be able to deepen the cooperative relationship with Kalbe Farma, which is one of the largest players in pharmaceutical industry in Indonesia.
The provision of this credit facility is a form of BNI's commitment as a national bank to support the development of priority sector businesses, including the healthcare and pharmaceutical industries.
According to Silvano, the trend of economic recovery is getting stronger in the middle of this year. Banking industry players continue to open gaps for growth in the performance of intermediation function to increase the leverage of economic recovery.
As a state-owned bank that focuses on lending in the corporate segment, PT Bank Negara Indonesia (Persero), Tbk. or BNI (stock code: BBNI) is currently actively transforming and focusing on lending to top tier companies in Indonesia.
Health sector, including pharmaceuticals, is one of the leading sectors that is BNI's priority in terms of business development and lending.
"Of course, apart from this credit agreement, we will explore more potential collaborations with Kalbe Farma.
As a bank with digital transformation, of course, there are many digital products and solutions that can be our added value in increasing the synergy of partnerships with Kalbe Farma," he said.